Ranityle Suspension contains Ranitidine 75mg/5ml, an H2 receptor antagonist indicated for the management of gastric acid-related disorders such as ulcers, gastroesophageal reflux disease (GERD), and hyperacidity. It helps in reducing stomach acid production and promoting healing of gastric mucosa.
Ranitidine works by blocking histamine H2 receptors in the stomach lining, thereby reducing acid secretion and providing relief from heartburn, acidity, and ulcer symptoms. Its suspension form ensures convenient dosing, especially for pediatric and adult patients.
For distributors and healthcare suppliers, Ranityle Suspension is a high-demand gastroprotective therapy product, widely used in hospitals, gastroenterology clinics, and community healthcare settings. The prevalence of acid-related disorders ensures consistent market demand throughout the year.
Adding Ranityle Suspension to your gastric and anti-ulcer therapy segment creates strong opportunities in pharmacies, hospitals, clinics, export markets, and third-party manufacturing. Its reliable efficacy, prescriber confidence, and broad patient applicability make it a valuable addition to pharmaceutical distribution portfolios.